Ricardo Jorge Fernandes

  • Oncobiology
  • cancer
  • breast cancer
  • kidney cancer
  • prostate cancer
  • bladder cancer
  • cancer biomarkers
  • medicine

Biologist and Medical Oncologist, with a background on translational research. Started in 2005, with a degree (BSc) on Applied Biology and thesis “Study of the therapeutic molecular target, EGF/EGFR, in bladder tumours” at ICVS – UMinho. From there, a master degree in Medicine (2012) with a master thesis “Impact of HOXA9 Expression in the Response of Glioblastoma to Temozolomide and Patient Prognosis”. The area of expertise was chosen: Oncology. Finished the Medical Oncology internship in 2019 and currently working at Braga Hospital as a specialist, with a special interest in breast cancer and urological cancers. Involved in clinical trials as a sub-investigator as well as principal investigator. Member of the Cancer Biomarkers and Therapeutics Research Team at ICVS – UMinho and invited assistant professor at the School of Medicine (UMinho).

Scientific Highlights

1. Impact of the COVID-19 Pandemic on Breast Cancer Management in Portugal: A Cross-Sectional Survey-Based Study of Medical Oncologists. Alpuim Costa D, et al Oncol Ther. (2022 )
2. Synthesis of new proteomimetic quinazolinone alkaloids and evaluation of their neuroprotective and antitumor effects. Long S., Resende D. I., Kijjoa A., Silva A., Fernandes R., Xavier C. P. & Pinto. M. M. Molecules 24.3 (2019)
3. A case of hemolytic anemia or macroglobulinemia: a complex diagnosis
Fernandes R, Malveiro A, Lino I, Almeida J, Azevedo F. Revista Online de Casos Clínicos, Sociedade Portuguesa de Medicina Interna (2016)
4. Impact of EGFR genetic variants on glioma risk and patient outcome
Costa B.M., Viana-Pereira M., Fernandes R., Costa S., Linhares P., Vaz R.,
Pardal F. Cancer Epidemiology and Prevention Biomarkers (2011)
2CA-Braga | Projeto de Investigação Clínica “Establishment of a patient-derived xenograft CAM model for in vivo validation of the new anticancer drug candidate SM01 – CAMAvatar